Syndicate Invests $26.7m in Microbiome Therapeutics Company BiomX


19 May 2017 --- A global syndicate which includes corporate venture funds Seventure Partners, Takeda Ventures and Johnson and Johnson Development Corporation has announced a $26.7 million (€24 million) investment in Israeli microbiome therapeutics company BiomX. 

BiomX focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. Its initial product candidates are based on bacteriophages (viruses which target and kill specific species or strains of bacteria). The company also uses unique technologies to identify microbiome targets for key diseases. 

The investment will be used for further developing BiomX’s drug candidate and obtain clinical proof of concept for the lead compound enabling the company to develop its world-leading IP and position itself as a major player in developing prescription-drug (Rx) therapeutics using scientific insights from its microbiome research.

“Since the beginning of the 20th Century, bacteriophage therapy has fascinated scientists by its ability to kill bacteria specifically and efficiently. But it lost out to antibiotics as a weapon against infectious diseases. BiomX is innovating by reviving this technology in the context of rebalancing the human microbiome to fight against chronic diseases,” says Eric de La Fortelle, Venture Partner at Seventure Partners.

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, comments: “The microbiome field has is complex with multiple approaches having synergistic roles in healthcare. BiomX’s approach using bacteriophage seeks to harness natural mechanisms to restore a healthy microbiome balance to the gut. Israel is widely recognized for its expertise and innovation in life sciences, and our investment in a new region reflects how we are expanding our investment horizons internationally.”

To contact our editorial team please email us at

Related Articles

Nutrition & Health News

Adisseo and Seventure Partners announce €24m first close of new fund for Animal Health and Nutrition

22 Mar 2018 --- French venture capital firm Seventure Partners has launched a venture capital fund targeted at supporting companies in the field of animal health, feed and nutrition, called AVF. The first close of AVF, at €24 million, is corner stoned by Adisseo, an industry heavyweight in the animal feed sector. AVF’s investment strategy will reportedly focus on two segments at the forefront of the modern agricultural and livestock revolution: animal health, feed and nutrition and digital technologies serving the livestock industry.

Business News

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 --- Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, is seeing rapid progress from innovation into human trials, with five of its portfolio companies advancing their human microbiome products with varying modalities and therapeutics targets in clinical trials.

Business News

LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

Nutrition & Health News

Gut Reaction – Microbiome Can Predict Body’s Response to Junk Foods

06 Jul 2017 --- Chemical signatures from gut bacteria which show up in urine can be used to predict how the body will respond to a “junk” diet. This is according to new research that has shown that certain compounds, produced by microbes in the guts of mice, could be used to show which animals are at greater risk of becoming obese or developing health conditions such as diabetes or cardiovascular disease (CVD).

Business News

Health for Life Capital Partakes in US$13.2m Financing of Japanese Microbiome Firm

05 Jul 2017 --- Seventure’s Health for Life Capital investment vehicle has participated in a US$13.1 million financing of Japanese biotech company Anaeropharma Science, Seventure Partners announced in a press release. Anaeropharma Science, based in Tokyo, Japan, is developing novel genetically enhanced bacteria to fight tumors. 

More Articles